Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.95, while BIO-TECHNE Corp trades at $72.23 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SHY | TECH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $83.18 | $72.29 |
52-Week Low | $81.77 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.955, up 0.12% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional accumulation, including Barry Investment Advisors increasing its stake by 48.1% in Q2 2026 (SEC filing, August 10, 2026), amid fluctuating Treasury yields influenced by inflation data and Middle East tensions. The ETF maintains a steady dividend schedule, with recent payouts of $0.24-$0.25 per share.
Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income stability but limited growth. Risks include Fed policy shifts and oil-price volatility, while institutional buying signals defensive positioning. The neutral oscillator reading suggests short-term consolidation near current levels.
Bio-Techne (TECH) trades at $72.11, down 0.01% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q2 2026. The company reported Q4 2026 revenue of $321.2 million, with organic growth of 3%, and declared a $0.08 dividend. However, net income margin has declined from 25.09% in 2023 to 6.01% in 2025, and valuation ratios like P/E of 103.09 remain elevated.
The outlook is mixed: strong cash flow and institutional interest support upside, but high valuation and margin compression pose risks. Analysts are evenly split between Buy and Hold, with a consensus price target of $71.67, slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
